Better
Treatments,
More Tomorrows

Better
Treatments,
More Tomorrows

We Are
Advancing

a growing pipeline of product candidates for the treatment of highly resistant cancers and viruses.

Innovative
Therapies

through the use of proprietary technologies and data to develop a next generation anthracycline, immune/transcription modulators (STAT3 inhibitors) and metabolism/glycosylation inhibitors.

Innovative
Therapies

through the use of proprietary technologies and data to develop a next generation anthracycline, immune/transcription modulators (STAT3 inhibitors) and metabolism/glycosylation inhibitors.

The Moleculin Opportunity

A Three-Part Series Presented by CEO, Walter Klemp

Part 1:

Recent Progress and Emphasizes the Potential Value of Annamycin

Part 2:

AML Patient Journey and the Annamycin Opportunity

Part 3:

Pathway Towards a Potential Annamycin Approval in AML

Priority Development Pipeline

AML Patient Journey and the Annamycin Opportunity 

Latest Releases

Stock Information

NASDAQ: MBRX

NASDAQ: MBRX

Corporate

Presentation

Corporate

Presentation